- Home
- ITRG vs ITOS Comparison
ITRG vs ITOS Comparison
Compare ITRG & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- ITOS
- Stock Information
- Founded
- ITRG 1997
- ITOS 2011
- Country
- ITRG Canada
- ITOS United States
- Employees
- ITRG N/A
- ITOS N/A
- Industry
- ITRG Precious Metals
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITRG Basic Materials
- ITOS Health Care
- Exchange
- ITRG Nasdaq
- ITOS Nasdaq
- Market Cap
- ITRG 227.8M
- ITOS 270.7M
- IPO Year
- ITRG N/A
- ITOS 2020
- Fundamental
- Price
- ITRG $1.69
- ITOS $6.51
- Analyst Decision
- ITRG Strong Buy
- ITOS Strong Buy
- Analyst Count
- ITRG 1
- ITOS 3
- Target Price
- ITRG $2.75
- ITOS $26.00
- AVG Volume (30 Days)
- ITRG 968.9K
- ITOS 413.2K
- Earning Date
- ITRG 05-13-2025
- ITOS 05-09-2025
- Dividend Yield
- ITRG N/A
- ITOS N/A
- EPS Growth
- ITRG N/A
- ITOS N/A
- EPS
- ITRG N/A
- ITOS N/A
- Revenue
- ITRG $30,350,000.00
- ITOS $35,000,000.00
- Revenue This Year
- ITRG $490.21
- ITOS N/A
- Revenue Next Year
- ITRG $37.03
- ITOS $31.74
- P/E Ratio
- ITRG N/A
- ITOS N/A
- Revenue Growth
- ITRG N/A
- ITOS 177.89
- 52 Week Low
- ITRG $0.73
- ITOS $4.80
- 52 Week High
- ITRG $1.69
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- ITRG 70.34
- ITOS 55.62
- Support Level
- ITRG $1.05
- ITOS $4.80
- Resistance Level
- ITRG $1.88
- ITOS $5.55
- Average True Range (ATR)
- ITRG 0.12
- ITOS 0.43
- MACD
- ITRG 0.06
- ITOS 0.13
- Stochastic Oscillator
- ITRG 77.58
- ITOS 97.16
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.